Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 11 March 2022

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for therapeutic goods in Australia, ensuring that such goods are safe, of high quality, and effective for their intended use. This Act was introduced to address the need for comprehensive regulation of therapeutic goods, including medicines, medical devices, and blood and blood components. The Act is administered by the Therapeutic Goods Administration (TGA), an agency of the Department of Health, and aims to protect public health by ensuring that therapeutic goods meet appropriate standards for quality, safety, and efficacy. The revocation of manufacturing licences under this Act is a mechanism by which the TGA can enforce compliance with these standards and maintain the integrity of the therapeutic goods market. The notice published on 11 March 2022 by Katherine Clark, as the Delegate of the Secretary, reflects the TGA’s role in managing the licensing of therapeutic goods manufacturers in accordance with the Act’s provisions.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacturing, supply, and importation of therapeutic goods within Australia. This encompasses a broad range of products, including medicines, medical devices, blood, and tissues, ensuring that they meet the necessary quality, safety, and efficacy standards. The Act primarily governs manufacturers, importers, and suppliers of these goods, requiring them to obtain appropriate licences and comply with regulatory requirements. Geographically, the Act has a national reach, applying across the Commonwealth of Australia, including states and territories, to ensure uniform standards and oversight of therapeutic goods throughout the country. The Act includes provisions for the revocation of manufacturing licences, as evidenced by the revocation of licences for Sphere Healthcare Pty Ltd, Baxter Healthcare Pty Ltd, Botanical Resources Australia Pty Ltd, and Fresenius Medical Care Australia Pty Ltd. These revocations were made at the request of the manufacturers, illustrating a key mechanism by which the Therapeutic Goods Administration enforces compliance. While the primary Act lays down the foundational requirements and regulatory framework, its application can be further detailed or extended through subordinate instruments such as regulations and codes of practice, ensuring a comprehensive and adaptable governance structure for therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA), includes provisions for the regulation of therapeutic goods within Australia. Section 41(1)(d) of this Act allows the Secretary to revoke a licence for the manufacture of therapeutic goods under certain circumstances. This legislative power is exercised through the issuance of a written notice, which is evidenced in the published revocation of manufacturing licences for Sphere Healthcare Pty Ltd, Baxter Healthcare Pty Ltd, Botanical Resources Australia Pty Ltd, and Fresenius Medical Care Australia Pty Ltd. Each of these revocations was conducted at the request of the respective manufacturers, as stated in the notice. The obligations imposed by the Therapeutic Goods Act 1989 on entities holding manufacturing licences include adherence to stringent quality and safety standards. Manufacturers must ensure that their products meet the regulatory requirements outlined in the Act and any accompanying regulations. These obligations encompass the maintenance of appropriate manufacturing practices, the provision of accurate and comprehensive information about the therapeutic goods, and the implementation of systems to monitor and report adverse events related to the products they manufacture. Failure to comply with the obligations set out in the Therapeutic Goods Act 1989 can result in severe consequences. The Act provides for both civil and criminal penalties for breaches of its provisions. Under the criminal provisions, individuals and corporations can be prosecuted for offences such as manufacturing therapeutic goods that do not comply with the standards set out in the Act, or for providing false or misleading information in relation to therapeutic goods. Penalties for these offences can include substantial fines, with maximum penalties varying depending on the specific offence and the severity of the breach. Additionally, the Act allows for the imposition of civil penalties for less severe breaches, which can also include fines, further emphasising the importance of compliance with the Act's requirements.